全文获取类型
收费全文 | 282796篇 |
免费 | 31707篇 |
国内免费 | 2446篇 |
专业分类
耳鼻咽喉 | 9620篇 |
儿科学 | 10041篇 |
妇产科学 | 8266篇 |
基础医学 | 28269篇 |
口腔科学 | 4951篇 |
临床医学 | 32249篇 |
内科学 | 70623篇 |
皮肤病学 | 13612篇 |
神经病学 | 24024篇 |
特种医学 | 12322篇 |
外科学 | 62618篇 |
综合类 | 642篇 |
现状与发展 | 72篇 |
一般理论 | 4篇 |
预防医学 | 11494篇 |
眼科学 | 8698篇 |
药学 | 5428篇 |
中国医学 | 53篇 |
肿瘤学 | 13963篇 |
出版年
2023年 | 4813篇 |
2021年 | 3132篇 |
2020年 | 6051篇 |
2019年 | 2153篇 |
2018年 | 7519篇 |
2017年 | 7466篇 |
2016年 | 8597篇 |
2015年 | 11619篇 |
2014年 | 19265篇 |
2013年 | 20630篇 |
2012年 | 9135篇 |
2011年 | 8951篇 |
2010年 | 14190篇 |
2009年 | 18137篇 |
2008年 | 9512篇 |
2007年 | 7678篇 |
2006年 | 10330篇 |
2005年 | 7279篇 |
2004年 | 6277篇 |
2003年 | 3670篇 |
2002年 | 2438篇 |
2001年 | 4467篇 |
2000年 | 3628篇 |
1999年 | 4023篇 |
1998年 | 4636篇 |
1997年 | 4495篇 |
1996年 | 4440篇 |
1995年 | 4420篇 |
1994年 | 3237篇 |
1993年 | 2836篇 |
1992年 | 2854篇 |
1991年 | 2663篇 |
1990年 | 2311篇 |
1989年 | 2220篇 |
1988年 | 1968篇 |
1987年 | 1873篇 |
1986年 | 1853篇 |
1985年 | 1556篇 |
1984年 | 1489篇 |
1982年 | 1492篇 |
1933年 | 1493篇 |
1932年 | 1483篇 |
1931年 | 1472篇 |
1930年 | 1653篇 |
1928年 | 1530篇 |
1927年 | 1497篇 |
1926年 | 1584篇 |
1925年 | 1544篇 |
1924年 | 1611篇 |
1923年 | 1465篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
4.
Elizabeth A. Mosley PhD MPH Amy J. Schulz PhD MPH MSW Lisa H. Harris MD PhD Barbara A. Anderson PhD 《Women & health》2020,60(7):806-820
ABSTRACT Abortion is legal in South Africa, but negative abortion attitudes remain common and are poorly understood. We used nationally representative South African Social Attitudes Survey data to analyze abortion attitudes in the case of fetal anomaly and in the case of poverty from 2007 to 2016 (n = 20,711; ages = 16+). We measured correlations between abortion attitudes and these important predictors: religiosity, attitudes about premarital sex, attitudes about preferential hiring and promotion of women, and attitudes toward family gender roles. Abortion acceptability for poverty increased over time (b = 0.05, p < .001), but not for fetal anomaly (b = ?0.008, p = .284). Highly religious South Africans reported lower abortion acceptability in both cases (Odds Ratio (OR)anomaly = 0.85, p = .015; ORpoverty = 0.84, p = .02). Premarital sex acceptability strongly and positively predicted abortion acceptability (ORanomaly = 2.63, p < .001; ORpoverty = 2.46, p < .001). Attitudes about preferential hiring and promotion of women were not associated with abortion attitudes, but favorable attitudes about working mothers were positively associated with abortion acceptability for fetal anomaly ((ORanomaly = 1.09, p = .01; ORpoverty = 1.02, p = .641)). Results suggest negative abortion attitudes remain common in South Africa and are closely tied to religiosity, traditional ideologies about sexuality, and gender role expectations about motherhood. 相似文献
5.
6.
T. Kapellen A. Galler K. Claus S. Heger D. Härtig Prof. Dr. W. Kiess 《Der Diabetologe》2006,2(2):167-181
Type 1 diabetes is one of the commonest chronic disorders encountered in children and adolescents. When it first becomes apparent in children, approximately 20% of them have clinical and biochemical signs of ketoacidosis (DKA). In the presence of unusual clinical symptoms it is necessary to consider the possibility of associated conditions, such as coeliac disease, immunothyroiditis and Addison’s disease. Children with diabetes must be treated by a multidisciplinary team made up of paediatrician, paediatric diabetes specialist, psychologist, social worker, ophthalmologist, dietitian, nurse and diabetes counsellor, making it essential for them to be treated in regional specialised centres. They are treated in their own psychosocial environment and their families are involved in the therapy. Comprehensive, multidisciplinary treatment strategies have now made it possible for these patients to enjoy normal physical wellbeing and near-normal psychosocial development. Prevention and early treatment of of disturbances associated with diabetes remain an important concern. The fact that type 2 diabetes must now be looked for in overweight children and adolescents is a new aspect of diabetes medicine. 相似文献
7.
Chronic transplant dysfunction is a complex dynamic pathogenic process. Clinically, a decrease in glomerular filtration rate (GFR) becomes apparent leading to chronic renal insufficiency and dialysis or death from cardiovascular events. Chronic transplant dysfunction can develop into a chronic alIograft nephropathy (CAN) as a specific entity with dynamic progression. CAN includes a collection of immunologic and non-immunologic factors, rejection, ischemia time, donor and recipient characteristics and toxicity of calcineurin inhibitors. Despite improvements in immunosuppression, the long-range prognosis of renal allografts has not improved. Whether modern immunosuppressive concepts with reduction or avoidance of calcineurin inhibitors and a therapy based on antimetabolites, such as mycophenolate or mTOR-inhibitors could lead to a prolongation of transplant survival, remains to be seen. 相似文献
8.
9.
Dr. med. Dr. Univ. Rom A. Zeyfang 《Der Diabetologe》2006,2(3):262-274
Zusammenfassung In Deutschland leiden 25% der über 70-Jährigen unter einem Diabetes mellitus. Biologisch ältere, multimorbide und in ihren Funktionen beeinträchtigte geriatrische Patienten benötigen spezielle Vorgehensweisen bei Zielplanung, Allgemeinmaßnahmen und Pharmakotherapie. Auf der Basis der vorhandenen Leitlinien werden gesicherte Erkenntnisse dargestellt und Empfehlungen zu den Besonderheiten der Therapie des geriatrischen Diabetespatienten gegeben. Besonderes Augenmerk liegt dabei auf der Interaktion von geriatrischen Syndromen und Diabetes sowie der Verbesserung der Lebensqualität. 相似文献
10.